Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | CDK9 | P50750 | 4/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657918 | 0.90 | BRD4 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4281083 | 0.90 | BRD4 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4286098 | 0.88 | PAK1 (0.43) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4282165 | 0.88 | PAK1 (0.43) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4278002 | 0.87 | CCNA2 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4282435 | 0.87 | CCNA2 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4290632 | 0.86 | CDK2 (0.42) | BRD4CDK9PAK1CDK2KCNH2 | |
| SCHEMBL4290612 | 0.86 | PAK1 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4281635 | 0.86 | PAK1 (0.42) | BRD4CDK9PAK1CCNA2CDK2 | |
| SCHEMBL4277420 | 0.86 | CDK2 (0.42) | BRD4CDK9PAK1CDK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | BRD4 535/4885CDK9 14/4885PAK1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.